74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Embecta Corp
Closed
SectorHealthcare
11.74 4.73
Overview
Share price change
24h
Min
11
Max
11.84
Income | -41M -26M |
|---|---|
Sales | -24M 262M |
P/E Sector Avg | 11.02 57.333 |
EPS | 0.65 |
Dividend yield | 5.5 |
Profit margin | -10.042 |
Employees | 2,100 |
EBITDA | 5.1M 39M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +82.71% upside |
Dividend yield Sector Avg | 5.50% 2.63% |
|---|---|
Next Earnings | 9 May 2025 |
Next Dividend date | 13 Jun 2025 |
Market Cap | 659M |
|---|---|
Previous open | 7.01 |
Previous close | 11.74 |
Embecta Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Embecta Corp Forecast
Price Target
By TipRanks
82.71% upside
12 Months Forecast
Average 20.5 USD 82.71%
High 26 USD
Low 15 USD
Based on 2 Wall Street analysts offering 12 month price targets forEmbecta Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Embecta Corp
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
